Opposing cardioprotective actions and parallel hypertrophic effects of δPKC and εPKC

Leon Chen, Harvey Hahn, Guangyu Wu, Che Hong Chen, Tamar Liron, Deborah Schechtman, Gabriele Cavallaro, Lucia Banci, Yiru Guo, Roberto Bolli, Gerald W. Dorn, Daria Mochly-Rosen

Research output: Contribution to journalArticlepeer-review

485 Scopus citations


Conflicting roles for protein kinase C (PKC) isozymes in cardiac disease have been reported. Here, δPKC-selective activator and inhibitor peptides were designed rationally, based on molecular modeling and structural homology analyses. Together with previously identified activator and inhibitor peptides of εPKC, δPKC peptides were used to identify cardiac functions of these isozymes. In isolated cardiomyocytes, perfused hearts, and transgenic mice, δPKC and εPKC had opposing actions on protection from ischemia-induced damage. Specifically, activation of εPKC caused cardioprotection whereas activation of δPKC increased damage induced by ischemia in vitro and in vivo. In contrast, δPKC and εPKC caused identical nonpathological cardiac hypertrophy; activation of either isozyme caused nonpathological hypertrophy of the heart. These results demonstrate that two related PKC isozymes have both parallel and opposing effects in the heart, indicating the danger in the use of therapeutics with nonselective isozyme inhibitors and activators. Moreover, reduction in cardiac damage caused by ischemia by perfusion of selective regulator peptides of PKC through the coronary arteries constitutes a major step toward developing a therapeutic agent for acute cardiac ischemia.

Original languageEnglish
Pages (from-to)11114-11119
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Issue number20
StatePublished - Sep 25 2001


Dive into the research topics of 'Opposing cardioprotective actions and parallel hypertrophic effects of δPKC and εPKC'. Together they form a unique fingerprint.

Cite this